Come join us on Saturday, May 2 for the @bloodcancerunited.bsky.social 2026 Rocky Mountain Blood Cancer Conference! I'll be speaking about Waldenström macroglobulinemia and novel therapeutic approaches on the horizon. #lymsm #wmsm
bloodcancerunited.org/RMBCC26
Stage IA NLPHL outcomes
- 779/2243 pts Stage IA
- completely resected: better PFS if +RT
- unresected: R monotx & ABVD with worse PFS as compared to RT +/- ABVD
- not enough N to analyze R-CHOP
RT alone great option in both resected & unresected dx. #lymsm
ashpublications.org/bloodadvance...
New anatomic classification R/R SCNSL
- 162 pts, 42 with both CNS+systemic dx
- leptomeningeal dx = inferior OS in MV model
- 4 subtypes w/ distinct PFS & OS: parenchymal +/- systemic and LM +/- systemic (see KM curve)
Useful schema in future trials. #lymsm
onlinelibrary.wiley.com/doi/10.1002/...
Glofitamab CNS penetration @bloodadvances.bsky.social
- 8 PCNSL/SCNSL, 7 LBCL, 1 BL
- 3/8 CRS (all G1-2), no ICANS
- 7/8 response (4 CR, 3 PR)
- 2 PCNSL durable CRs
- CSF: +glofi with activity in vitro
Bridging to CAR for SCNSL or even monotx for PCNSL. #lymsm
ashpublications.org/bloodadvance...
Tazemetostat pulled from the market this morning due to secondary malignancy risks seen in the SYMPHONY-1 trial. #lymsm
We found ORR 70 (CR 45%) of bispecifics after CAR-T, with mPFS 8.9 mos and median DOR and OS not reached. Patients with late post-CAR relapse (>6 months) who were treated with CD20 bispecifics had better outcomes. Infections were common, highlighting cumulative immunosuppression. #lymsm
Many thanks to @onclive.bsky.social for reviewing our #Tandem26 abstract on outcomes of CD20 bispecifics after CD19 CAR in R/R MCL, an analysis from the CUBIC Consortium. #lymsm #tcellrx
Abstract link: www.astctjournal.org/article/S266...
www.onclive.com/view/real-wo...
Infx post CD20 bispecifics @bloodadvances.bsky.social
- 122 pts
- 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV)
- 76% cumulative incidence infx at 2 yrs
- 8% G5 infx at 1 year
Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm
ashpublications.org/bloodadvance...
Elated to be presenting our MAGIC-ONC vascular access appropriateness recommendations in patients with cancer to the @hms-mi.bsky.social consortium today! Be sure to read the full paper published @annalsofim.bsky.social: www.acpjournals.org/doi/10.7326/... #medsky #oncsky cc @davidpaje.bsky.social
CD3xCD20 BsAb CNS lymphoma #ASH25
- 28 pts from CUBIC (22 glofi), 18 active CNSi
- 6-mo PFS/OS 44%/81%
- active CNSi: ORR 56% (CR 33%)
- 67% received combo tx (BTKi, len, IT chemo)
Outcomes with active CNSi similar to trials. Need more pts & longer f/u. #lymsm #tcellrx
CNS relapse of LBCL after CAR-T #ASH25
- 1102 pts R/R LBCL: 79% CAR, 21% CIT
- 1.6% incidence of CNS relapse after CAR (2.2% CIT cohort)
- time from CAR to CNSr 4.7 mo
Corroborates known CAR CNS penetration. Upfront CAR if high CNSr risk? #lymsm #tcellrx
3-year f/u STARGLO #ASH25
- glofi-GemOx: mPFS 14 (v 3 mos), mOS 26 (v 13 mos)
- in 2L: mPFS 20 (vs 5 mos), mOS NR (vs 14 mos)
- 20% G3+ infx AEs in glofi arm
Maybe a PFS plateau on KM curves if you squint... #lymsm #tcellrx
Q-TWIST analysis of CARTITUDE-4 @surbhisidanamd.bsky.social #ASH25: 9-13 month gain of quality-adjusted time w/o symptoms/toxicity as compared to SOC, and this includes time with high-grade ICANS. #mmsm #tcellrx
Patients with poor baseline HRQoL in ALPINE trial still had PFS benefit with zanu (vs ibrutinib). #lymsm #ASH25
Spiritual wellness & QoL PROs in acute leukemia #ASH25
- 30 pts, 27% AYA, 53% AML
- higher spiritual wellness = better QoL across first 30 days of treatment (at baseline & 30 days)
Opportunity to improve QoL/PROs with spiritual support services at diagnosis. #leusm
Time & financial tox work at #ASH25: 66 pts (40 #lymsm, 26 #mmsm) treated with BsAb or CAR-T. ~25% had significant FT at 3 months, and time tox decreased over time. FT & TT both associated with worse QoL & psychological distress.
Glofi+obin 1L HTB FL #ASH25
- 35 pts, 63% FLIPI 3-5
- ORR 100% (CR 88%)
- pretx with 4 doses of obinu: 40% any-grade CRS, all G1 except 1 case of G3
- 31% infx (all G1-2)
- only 7.5 mo F/U: 8-mo PFS 95%
More chemo-free options in 1L FL; need more f/u. #lymsm
Epidemiological data on NLPHL presented at the @ash.hematology.org #ASH25 Annual Meeting. Using a UK-based cancer registry, higher incidence of NLPHL in Black and Asian patients as compared to White patients. 5-year OS and relative survival of >90%. #lymsm #NLPHLsm
More time toxicity work from #ASH25: adults with ALL spent 25% of days over the first year physically interacting with the health care system. Tremendous potential to improve this with novel agents and/or hospital at home care delivery models. #leusm #AYAsm #timetox @ash.hematology.org
Pirto v venetoclax in R/R WM #ASH25
- 91 pts: 64 VEN
- MV model:⬇️PFS w/ ven if TP53mut;⬇️MRR & PFS w/ pirto if CXCR4mut
- no diff in MRR or PFS between pirto & VEN
- transition from BTKi to VEN = 62% IgM rebound (didn't happen w/ pirto)
Genetic-based tx decisions in WM! #lymsm
A time toxicity analysis of CAR-T in NHL by Trotier et al. from #ASH25 (using claims data) found a 1-year median of 52 contact days, very similar to our multicenter study. Very promising that we can use claims data to generate these time toxicity data. #lymsm cc @uduranimd.bsky.social
These data support shared decision-making in R/R FL and enable incorporation of patient preferences regarding duration of disease control and time burden of treatment. #lymsm
Abstract here: ashpublications.org/blood/articl...
In our study of real-world survival & time toxicity of CAR-T vs BsAb in R/R FL, we found that CAR-T resulted in superior PFS but more time toxicity, with no difference in OS.
Over first year, 51-64 physical healthcare contact days with CAR-T vs 36-38 with BsAb. #lymsm
www.vumedi.com/video/ash-20...
CU Cancer Center member Ajay Major (@majorajay.bsky.social), MD, MBA, led a study of more than 25,000 long-term childhood cancer survivors, to learn more about their rates of colorectal cancer and what their doctors can do about it ⬇️
https://bit.ly/3MkDl2t
Also no difference in hours spent at infusion center between IV vs SQ formulations.
Overall, these data are first & largest of patient-reported time burden with different bispecifics in FL & DLBCL, and provide concrete data to better counsel patients as part of shared decision-making. #ASH25 #lymsm
Significantly fewer all-cause visits with mosun in FL and glofi in DLBCL at 1.6 and 0.8 fewer visits, respectively, vs epcor.
50% reduction in hours spent on cancer-related care with mosun & glofi vs epcor (including less time recovering at home). #ASH25 #lymsm
Enrolled 60 patients w/ FL & 60 w/ DLBCL, all actively on BsAb therapies for >1 month. Over 1/4 were non-White, most urban/suburban, majority treated in academic centers. Majority had been on treatment for >4-6 months. #ASH25 #lymsm
At #ASH25, we presented our patient-reported time toxicity study in 120 pts w/ R/R FL & DLBCL on mosun, glofi & epcor. Mosun & glofi w/⬇️all-cause healthcare visits & hours spent on cancer-related care in past 30 days v epcor.
More details in this #thread. #lymsm
www.sciencedirect.com/science/arti...
